TargetMol

Tafetinib

Product Code:
 
TAR-T28911
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28911-1mg1mg£271.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28911-5mg5mg£571.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28911-10mg10mg£783.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28911-25mg25mg£1,139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28911-50mg50mg£1,500.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28911-100mg100mg£2,022.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28911-500mg500mg£3,990.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Tafetinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor used for the treatment of solid tumors.
CAS:
1032265-57-8
Formula:
C24H29FN4O2
Molecular Weight:
424.52
Pathway:
Tyrosine Kinase/Adaptors
Purity:
0.98
SMILES:
CCN(CC)CCNC(=O)c1c(C)[nH]c2c1CCCC2=C1C(=O)Nc2ccc(F)cc12
Target:
Tyrosine Kinases

References

1. Shao F, Zhu T, Tang F, Liu X. Simultaneous quantification of tafetinib (SIM010603), a novel potent inhibitor of receptor tyrosine kinase, and its major metabolite in dog plasma by HPLC-ESI/MS/MS and its application to a pharmacokinetic study. J Pharm Biomed Anal. 2013 Jul-Aug;81-82:50-5. doi: 10.1016/j.jpba.2013.02.041. PubMed PMID: 23624508. 2. Mao Y, Xia Z, Zhang X, Zong Y, Zhu L, Yuan B, Lu G. Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs. Food Chem Toxicol. 2012 May;50(5):1256-70. doi: 10.1016/j.fct.2012.02.007. PubMed PMID: 22343322. 3. Wang D, Tang F, Wang S, Jiang Z, Zhang L. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor. Cancer Chemother Pharmacol. 2012 Jan;69(1):173-83. doi: 10.1007/s00280-011-1681-1. PubMed PMID: 21638122.